Rolodex›Jonas Whitlam

Jonas Whitlam

Group Chief Financial Officer · Faraway Pharma

London, England, United Kingdom · LinkedIn ↗

Background

Group CFO at Faraway Pharma, where I oversee finance across three therapeutic subsidiaries and a recent bolt-on acquisition. Previously CFO at Calderwood Therapeutics and Ashstone Biopharma, both Oxford-cluster oncology companies I helped take from seed through Series B. I chair Larchmont Bio and remain close to the UK…

Experience20 yrsCompanies8

Career History

Jan 2021 – Present5 yr 6 moGroup Chief Financial Officer at Faraway PharmaLondon, England, United Kingdom

Series C · Pre-IPO180 → 240 FTEsGroup CFO · 3 subsidiaries

Group CFO across three Oxford-cluster oncology subsidiaries post-£62M Series C; runs consolidated reporting and audit committee, not cap-table building.

Aug 2018 – Present7 yr 11 moChairman at Larchmont Bio

Seed → Pre-Series A1–10 FTEsOncology · ADC platform

Non-exec chair at a Cambridge ADC seed-stage spinout; chaired £3.2M seed extension and Series A prep with Oxford Science Enterprises.

Sept 2015 – May 20204 yr 8 moChief Financial Officer at Calderwood Therapeutics

Series B → Trade sale34 → 71 FTEs£28M Series B · £140M trade saleOncology · Target-side M&A

Led £28M Series B then ran target-side process to £140M trade sale to a US mid-cap; structured R&D tax credit programme across the run.

Mar 2014 – Oct 20151 yr 7 moCFO at Ashstone BiopharmaLondon, England, United Kingdom

Pre-Seed → Series B4 → 22 FTEs£6M Series A · £19M Series BOncology · Small molecule

First finance hire; built function from scratch and led both £6M Series A and £19M Series B with EIS/SEIS layering in 19 months.

Education

FCA, Chartered Accountancy — Saltmoor College (1986–1991)

BA, Chemistry — Westcliff Institute (1983–1986)